ESSA Pharma (EPIX) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) from a buy rating to a hold rating in a research note released on Monday morning.

According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “

Several other brokerages have also weighed in on EPIX. Bloom Burton raised shares of ESSA Pharma from a hold rating to a buy rating in a report on Thursday, January 18th. ValuEngine raised shares of ESSA Pharma from a strong sell rating to a sell rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. ESSA Pharma has a consensus rating of Buy and a consensus target price of $4.63.

Shares of ESSA Pharma (NASDAQ:EPIX) opened at $0.23 on Monday. ESSA Pharma has a fifty-two week low of $0.15 and a fifty-two week high of $3.59. The company has a debt-to-equity ratio of -1.32, a current ratio of 1.26 and a quick ratio of 1.26.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last released its quarterly earnings results on Monday, December 11th. The company reported ($0.09) earnings per share for the quarter. research analysts expect that ESSA Pharma will post -0.29 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit